{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-069210","form_type":"8-K","ticker":"PRLD","cik":"0001678660","company_name":"Prelude Therapeutics Inc","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.034565+00:00","generated_at":"2026-06-07T14:56:43.484500+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Prelude Therapeutics raises $25M via pre-funded warrant private placement for SMARCA2 pipeline","bullets":["Gross proceeds ~$25M from sale of 7,936,759 pre-funded warrants at $3.1499 each, exercise price $0.0001.","Net proceeds estimated at $24.9M after offering expenses.","Funds primarily support SMARCA2 portfolio: IV molecule PRT3789 clinical development and oral program IND.","Cash runway now expected into 2026; closing expected Dec 13, 2023.","Warrants are immediately exercisable, subject to 4.99% beneficial ownership cap (waivable to 19.99%)."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-069210","json":"https://secwatch.observer/filing/0000950170-23-069210.json","markdown":"https://secwatch.observer/filing/0000950170-23-069210.md","text":"https://secwatch.observer/filing/0000950170-23-069210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/0000950170-23-069210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/prld-20231211.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:56:43.484500+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7c010440a3d25a6a7313fd698637fcf57c69b362","claim":"Prelude Therapeutics Inc entered into Amended and Restated Registration Rights Agreement with the Company and the Purchasers (effective 2023-12-11).","evidence_excerpt":"the Company and the Purchasers also entered into an Amended and Restated Registration Rights Agreement, dated as of December 11, 2023 (the “ Amended and Restated Registration Rights Agreement ”), providing for the registration for resale of the shares of Common Stock underlying the Pre-Funded Warrants","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/0000950170-23-069210-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the Company and the Purchasers"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"},{"claim_id":"b2f34e7edcd9b05f99dc822f0b802891555d23a0","claim":"Prelude Therapeutics Inc entered into Securities Purchase Agreement with certain institutional accredited investors (effective 2023-12-11).","evidence_excerpt":"On December 11, 2023, Prelude Therapeutics Incorporated, a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to 7,936,759 shares of the Company’s voting common stock, par value $0.0001 per share (the “ Common Stock ”), at a price of $3.1499 per warrant with an exercise price of $0.0001 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1678660/000095017023069210/0000950170-23-069210-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain institutional accredited investors"},{"label":"Effective","value":"2023-12-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}